MedElevator
Войти в исследования Clinica chimica acta; international journal of clinical chemistry · 2026
Analysis of genetic mutation distribution and metabolic characteristics in patients with primary carnitine deficiency from the Ganzhou area, China.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tu Xiangwen, Zhang Feng, Chen Junkun, Xie Chunlian
Аннотация
OBJECTIVE: To investigate genetic and metabolic profiles in primary carnitine deficiency (PCD) patients from Ganzhou.
METHODS: Newborns screened in Ganzhou were included. Free carnitine (C0) and acylcarnitines were quantified using tandem mass spectrometry (MS/MS). Positive cases underwent SLC22A5 gene analysis using next-generation and sanger sequencing. Clinical data, genetic results, and amino acid/acylcarnitine levels were collected for confirmed PCD patients. Regional PCD variant frequencies were analyzed. Metabolic profiles of normal infants and PCD patients were compared to identify disease features. Homozygous and compound heterozygous PCD groups were analyzed.
RESULTS: Screening 392,389 newborns identified 43 PCD cases (1:9125). Five maternal PCD cases were also identified. Of 48 PCD patients, 10 were homozygous and 38 heterozygous. Nineteen SLC22A5 mutations were found; the most common were c.51C > G (32.30%), c.1400C > G (26.00%), and c.428C > T (10.40%). In newborn PCD patients, C0 and multiple acylcarnitines including acetylcarnitine (C2), propionylcarnitine (C3), butyrylcarnitine (C4), isovalerylcarnitine (C5), hexanoylcarnitine (C6), octanoylcarnitine (C8), decanoylcarnitine (C10), dodecanoylcarnitine (C12), tetradecanoylcarnitine (C14), hexadecanoylcarnitine (C16), and octadecanoylcarnitine (C18) were significantly lower compared to controls (P < 0.05). Additionally, levels of glycine (GLY), ornithine (ORN), phenylalanine (PHE), tyrosine (TYR), and proline (PRO) were reduced(all P < 0.05), whereas arginine (ARG) was found to be elevated in PCD patients (P = 0.002). Furthermore, homozygous PCD patients exhibited lower C0 levels than heterozygous PCD patients (P = 0.049).
CONCLUSION: PCD incidence is high in Ganzhou Area. The most common mutations are c.51C > G, followed by c.1400C > G and c.428C > T. Multiple acylcarnitine reductions are a hallmark of PCD. Homozygous mutations correlate with lower C0 levels compared to heterozygous ones.
METHODS: Newborns screened in Ganzhou were included. Free carnitine (C0) and acylcarnitines were quantified using tandem mass spectrometry (MS/MS). Positive cases underwent SLC22A5 gene analysis using next-generation and sanger sequencing. Clinical data, genetic results, and amino acid/acylcarnitine levels were collected for confirmed PCD patients. Regional PCD variant frequencies were analyzed. Metabolic profiles of normal infants and PCD patients were compared to identify disease features. Homozygous and compound heterozygous PCD groups were analyzed.
RESULTS: Screening 392,389 newborns identified 43 PCD cases (1:9125). Five maternal PCD cases were also identified. Of 48 PCD patients, 10 were homozygous and 38 heterozygous. Nineteen SLC22A5 mutations were found; the most common were c.51C > G (32.30%), c.1400C > G (26.00%), and c.428C > T (10.40%). In newborn PCD patients, C0 and multiple acylcarnitines including acetylcarnitine (C2), propionylcarnitine (C3), butyrylcarnitine (C4), isovalerylcarnitine (C5), hexanoylcarnitine (C6), octanoylcarnitine (C8), decanoylcarnitine (C10), dodecanoylcarnitine (C12), tetradecanoylcarnitine (C14), hexadecanoylcarnitine (C16), and octadecanoylcarnitine (C18) were significantly lower compared to controls (P < 0.05). Additionally, levels of glycine (GLY), ornithine (ORN), phenylalanine (PHE), tyrosine (TYR), and proline (PRO) were reduced(all P < 0.05), whereas arginine (ARG) was found to be elevated in PCD patients (P = 0.002). Furthermore, homozygous PCD patients exhibited lower C0 levels than heterozygous PCD patients (P = 0.049).
CONCLUSION: PCD incidence is high in Ganzhou Area. The most common mutations are c.51C > G, followed by c.1400C > G and c.428C > T. Multiple acylcarnitine reductions are a hallmark of PCD. Homozygous mutations correlate with lower C0 levels compared to heterozygous ones.